AnGes : Notice Regarding Eiger BioPharmaceuticals, Inc.

April 12, 2024

Company Name: AnGes Inc.

Presentative: Ei Yamada, President & CEO

Notice Regarding Eiger BioPharmaceuticals, Inc.

AnGes Inc. entered into an exclusive distribution agreement in Japan with Eiger BioPharmaceuticals, Inc. ("Eiger") in May 2022 of Zokinvi (generic name: lonafarnib), a drug for Hutchinson-Gilford Progeria Syndrome and Progeroid Laminopathy, but we hereby announce that it has been revealed that Eiger has filed for Chapter 11 of the U.S. Bankruptcy Code.

We plan to purchase and sell Zokinvy, which received manufacturing and sales approval on January 18, 2019, from the company, but according to the company's announcement, it will sell Zokinvy to Sentynl Therapeutics, Inc. is currently under consideration, and as the details are undecided at this time, we will update you as new information becomes available.

The upfront and milestone payments associated with the above exclusive distribution agreement with Eiger have been completed, and there are currently no receivables or payables from or owed to Eiger.

At this time, the impact of this event on our consolidated earnings forecast is unknown, but we will promptly make an announcement if the impact on our consolidated earnings is expected to be significant.

(Note)This document has been translated from the Japanese original for reference purposes only.

In the event of any discrepancy between this translation and the Japanese original, the original shall prevail.